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There is an increasing need for innovative drug and prophylaxis discovery against malaria. The aim of the present study was to test
in vivo antiplasmodial activity of Croton macrostachyus H. (Euphorbiaceae) stem bark extracts from Kenyan folkloric medicine.
Inbred Balb/c mice were inoculated with erythrocytes parasitized with Plasmodium berghei (ANKA). Different doses (500, 250,
and 100mg/kg) of C. macrostachyus ethyl acetate, methanol, aqueous, and isobutanol extracts were administrated either after
inoculation (Peters’ 4-day suppressive test) or before inoculation (chemoprotective test) of the parasitized erythrocytes. All the
extracts showed significant suppression of parasitemia compared to control (𝑝 < 0.001): for the ethyl acetate extract in the range
of 58–82%, for the methanol extract in the range of 27–68%, for the aqueous extract in the range of 24–72%, and for the isobutanol
extract in the range of 61–80%. Chemoprotective effect was significant (𝑝 < 0.001) and the suppression caused by the ethyl acetate
extract was between 74 and 100%, by themethanol extract between 57 and 83%, and by the isobutanol extract between 86–92%.The
study showed that it is possible to inhibit the growth of the parasites by various stem bark extracts of C. macrostachyus in Balb/c
mice supporting the folkloric use of the plant against malaria.
1. Introduction
Medicinal plants have been used to cure parasitic infections
from time immemorial. About 40% of the modern drugs
and approximately 75% of drugs for infectious diseases are of
natural origin. The number of drug-like molecules possibly
present in the vast amount of species (fungi, bacteria, marine
invertebrates, and insects) has been estimated to exceed 1060
[1]. As a source of novel drugs, plants remain grossly under-
studied and underused, especially in the developed world
[2, 3]. A world health organization study has shown that 80%
of the world’s population relies solely upon medicinal plants
as a source of remedies for the treatment of diseases [2].
In China, India, Africa, and Latin America, modern drugs
are not available, or, if they are, they often prove to be too
expensive, unavailable, or inaccessible.
Malaria has historically been among the most deadly
parasitic infections in many tropical and subtropical regions
[4, 5]. Plasmodium falciparum is the most important agent of
human malaria, transmitted by the Anopheles mosquito into
the human blood. Worldwide 212 million malaria cases were
reported in 2015. Between 2010 and 2015 the new incident
malaria cases have decreased by 21% and mortality due to
malaria has decreased by 29%. Until recently, malaria used
to be the leading cause of death among children in sub-
Saharan Africa [5]. The improvements can be attributed
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to WHO-recommended core interventions, vector control,
chemoprevention, diagnostic testing, and treatment, which
all have proven to be cost-effective.
Emerging parasite resistance to antimalarial medicines
as well as mosquito resistance to insecticides could render
some of the current tools ineffective and trigger a new rise
in global malaria mortality. The resistance of P. falciparum
to 4-aminoquinolines (chloroquine, amodiaquine), antifols,
and dihydrofolate reductase inhibitors (pyrimethamine,
proguanil) in many endemic regions [6] and the emergence
of in vitro and in vivo resistance to aminoalcohols (quinine,
mefloquine, and halofantrine) have been reported in some
areas of Southeast Asia [7–9]. Except antifolate antimalarial
drugs other commonly used antimalarial agents are based on
plant-derived compounds, quinine, and artemisinin deriva-
tives, which remain vital drugs in the treatment of malaria
[10, 11].
Croton macrostachyus Hochst. ex Delile is a species of
the genusCroton L., Euphorbiaceae family, commonly known
as the spurge family. C. macrostachyus is regarded as a
multipurpose tree by subsistence farmers in Ethiopia, Kenya,
and Tanzania and the species has potential in playing an
important role in the primary healthcare. The bark, fruits,
leaves, roots, and seeds of C. macrostachyus are reported to
possess diverse medicinal properties and C. macrostachyus is
used as herbal medicine for at least 61 human and 20 animal
diseases and ailments [12]. In the distribution area there is a
high degree of medicinal use consensus for bleeding, blood
clotting, cancer, constipation, diarrhea, epilepsy, malaria,
pneumonia, purgative, ringworm, skin diseases or infections,
stomach ache, typhoid, worm expulsion, and wounds [13].
Leaf decoction, infusion, or maceration, stem or root bark,
and leaf sap of C. macrostachyus are taken as a purgative
and vermifuge, and the seed oil is a very powerful purgative
[12]. C. macrostachyus is also used for medicinal purposes
in combination with other plant species [12, 13]. Members of
the genus Croton and different parts of plant have been used
traditionally to treat infectious diseases such as measles and
typhoid fever in Kenya [14] and against malaria in Ethiopia
[15]. Antimalarial activity againstPlasmodiumberghei inmice
has been found from C. macrostachyus leaves [16, 17] and
from fruit and root [18]. In the present study antiplasmodial
activity of C. macrostachyus stem bark extracts was investi-
gated in a rodent model against P. berghei.
2. Materials and Methods
2.1. Plant Collection and Extraction. C. macrostachyus stem
bark was collected from the nature preserve of the University
of Eastern Africa, Baraton community in Nandi District of
Kenya. Baraton is located 10 km from Kapsabet, the head-
quarters of Nandi Central District. A voucher specimen was
deposited in the herbarium at the Department of Biological
Sciences, University of Eastern Africa, Baraton, and the
National Museums of Kenya for identification.
2.2. Preparation of the C. macrostachyus Extracts. The stem
bark extracts were prepared as described before [19]. Shortly,
the fresh stem bark was cut into small pieces using a pen
knife. The cut bark was air-dried in a shaded area for three
weeks. The air-dried bark was powdered using a mechanized
hand grinder.The powderedmaterial (500 g) was soaked into
ethyl acetate, absolute methanol, distilled water, or isobutanol
for 24 hours. The soaked extract was separated from the
plant residue by using a Buchner funnel. The extract was
separated from the solvent in a rotary evaporator device
(Rotavapor R300) at 40∘C. Each plant extract was then
dissolved in dimethyl sulfoxide (DMSO, Rankem, India) to
the concentration of 500mg/ml.
2.3. Preparation of Parasites. Plasmodium berghei strain
ANKA, a chloroquine-sensitive strain ofmalaria parasite, was
used in the in vivo study. The parasites were maintained by
injecting serial passages of infected blood intraperitoneally
(ip) into a Balb/c mouse and were then collected by cardiac
puncture.The percent parasitemia and the erythrocytes were
counted using the white blood cell count method. The blood
was then diluted with isotonic saline to obtain 2 × 107
parasitized erythrocytes/ml. The test animals were infected
intraperitoneally with 0.2ml of the parasitized erythrocytes.
2.4. Acute Toxicity Experiment. An acute toxicity test was
carried out to ascertain the safety of the extract. Six groups
of six clean uninfected BALB/c mice were used in the toxicity
test. For the test groups an oral dose of 0.2ml was given
per animal consisting of either 500mg/kg, 250mg/kg, or
100mg/kg of the extract according to the body weight. The
negative control group received 0.2ml of 10% Tween per
animal and the positive control group received artemether.
The weights of all animals were taken before and after the
experiment.The animals in each group were observed for any
change in physical activity and signs of abnormal growth or
disease condition. This included observations of mortality,
hair erection, tremors, lacrimation, convulsions, salivation,
diarrhea, and abnormal features in organs and blood.
2.5. Peters’ 4-Day Suppressive Test. The parasites used for this
study were obtained from the Kenya Government Medical
Research Institute (KEMRI), Center for Biotechnology and
Research Development (CBRD), Department ofMalaria. The
study design was a quantitative case control study described
by Peters in 1975 [20]. Infected mice groups were treated
with various extract concentrations and positive control
group was treated with artemether (PC) and negative control
group with 10% w/v Tween 80 (NC). Consent to use the
experimental animals in the study was obtained from the
ethical committee of the Kenya Medical Research Insti-
tute, Center of Biotechnology and Research Development,
Department of Malaria. Male 6–8 weeks old BALB/c mice
weighing 20 ± 2 g were selected for the in vivo study. Each
mouse was infected intraperitoneally by injecting 0.2ml of 2
× 107 erythrocytes/ml parasitized with Plasmodium berghei
strain ANKA. Groups of six mice were delivered orally with
either crude ethyl acetate, isobutanol, methanol, or aqueous
extracts using doses of 500, 250, and 100mg/kg body weight.
Each study group included PC and NC groups. The plant
fractions were dissolved in 10% w/v Tween 80 with the aid
of ultrasonication and diluted with distilled water to the test
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Table 1: Peters’ 4-day suppressive test. Parasitemia (%) in Plasmodium berghei inoculatedBALB/c mice after treatment withC. macrostachyus
stem bark extracts.




PC 2.15 ± 0.22 0.51 ± 0.23 0.15 ± 0.09 0.00 ± 0.00
500 3.18 ± 0.42 5.84 ± 0.45 5.27 ± 0.38 3.56 ± 0.57
250 7.26 ± 0.31 12.17 ± 0.66 10.44 ± 0.56 7.16 ± 1.28
100 6.64 ± 0.54 13.30 ± 0.67 14.16 ± 0.56 4.97 ± 1.59
NC 17.39 ± 0.27 18.33 ± 0.38 18.72 ± 0.90 18.20 ± 1.30
∗In each experiment a group of six mice were examined. The values represent the mean and standard deviation; PC = positive artemether control; NC =
negative 10% Tween 80 control; EtOAc = ethyl acetate extract; MeOH =methanol extract; H2O = aqueous extract; isoBuOH = isobutanol extract.
concentrations. On days 0, 1, 2, and 3 the animals were treated
once orally with the different doses of the extracts in a volume
of 0.02ml/g body weight. The mice received NAFAG pellets
(9009 PAB – 45) (Nafag AG, Switzerland) as a diet and were
held at room temperature. The survival of the mice in all
the groups was checked twice a day. Parasitized erythrocytes
(RBC) were counted in Giemsa stained thin films from tail
blood on day 4. The average parasitemia was calculated as
%Parasitemia = (Number of parasitized RBC




The percentage suppression of parasitemia (PSP) for each
plant extract was calculated as [21]
Suppression%
= Parasitemia in negative control − Parasitemia in study group
Parasitemia in negative control
× 100.
(2)
2.6. Chemoprotective Activity. The chemoprotective prophy-
laxis in vivo study was set up and carried out by first
treating the animals for four days with the different doses
of the studied extracts before exposing them to infection.
BALB/c male mice of 6–8 weeks old weighing 20 ± 2 g were
selected for the chemoprotective study. For each extract,
6 animals were selected as positive controls and negative
controls and for test animals. Three different doses of the
prepared extracts of 500, 250, and 100mg/kg body weight
were administrated orally. Each individual in a group of
thirty BALB/c mice was infected by injecting 0.2ml of 2 ×
107 parasitized erythrocytes/ml intraperitoneally. The mice
received NAFAG pellets (9009 PAB-45) as a diet and were
held at room temperature. The survival of the mice in all
groups was recorded twice a day. Parasitized erythrocytes
were counted in Giemsa stained thin films prepared from tail
blood onday 4.Thepercentage suppression of parasitemia for
each plant extract was calculated.
2.7. Statistical Analysis. Data are expressed as the mean ± the
standard error of the mean. One-way analysis of variance
(ANOVA) followed by Tukey’s honest significant difference
post hoc test was used to determine statistical significance in
the comparisons of parasitemia suppression. Values of 𝑝 <
0.001 were considered statistically significant.
3. Results
3.1. Acute Toxicity Experiment. The results from the toxicity
experiment showed that all animals in the ethyl acetate,
methanol, and water extract groups were normal during the
observations and at the end of the study period. The mice of
the isobutanol extract treatment group showed signs of acute
toxicity. They showed signs of tremor on the third day. On
a closer observation, the white fur seemed thin and slight
and was erected. None of the animals experienced salivation,
lacrimation, diarrhea, or convulsions. Two of the six mice in
the isobutanol dose group of 500mg/ml died before the end
of the treatment period.
3.2. In Vivo Peters’ 4-Day Suppressive Test. The parasitemia
in the negative control group was significantly higher than
in any of the treatment groups (𝑝 < 0.001) (Table 1). All the
animals in the positive control group displayed suppression
of parasitemia of 88–100% (Table 2).The ethyl acetate extract
induced 82%, 58%, and 62% suppression, the methanol
extract induced 68%, 34%, and 27%, and the aqueous extract
72%, 44%, and 24% suppression for the doses of 500, 250,
and 100mg/kg, respectively. For the doses of 500, 250, and
100mg/kg the isobutanol extract induced the suppression of
80%, 61%, and 73%, respectively (Table 2).
3.3. Chemoprotective Activity. In the chemoprotective assay
the parasitemia in the negative control groupwas significantly
higher than in any of the test group (𝑝 < 0.001) (Table 3).
All the animals in the positive control group displayed
suppression of parasitemia of 99% (Table 4). In the ethyl
acetate extract group suppression of parasitemia was 100%,
93%, and 74%, in the methanol extract group 83%, 65%, and
57%, and in the isobutanol extract group 92%, 84%, and
86% for the doses of 500, 250, and 100mg/kg, respectively
(Table 4).
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Table 2: Suppression of parasitemia (%) in Plasmodium berghei infected BALB/c mice in the Peters’ 4-day suppressive test after treatment
with C. macrostachyus stem bark extracts.




500 82 68 72 80
250 58 34 44 61
100 62 27 24 73
PC 88 97 99 100
∗In each experiment a group of six mice were examined; PC = positive artemether control; EtOAc = ethyl acetate extract; MeOH = methanol extract; H2O =
aqueous extract; isoBuOH = isobutanol extract.
Table 3: Chemoprotective assay. Parasitemia (%) in the infected








PC 0.20 ± 0.14 0.24 ± 0.17 0.10 ± 0.08
500 0.02 ± 0.02 2.73 ± 0.18 1.33 ± 0.54
250 1.23 ± 0.65 5.66 ± 0.40 2.74 ± 0.27
100 4.51 ± 1.59 6.94 ± 0.18 2.41 ± 0.33
NC 17.36 ± 0.86 16.10 ± 0.66 16.77 ± 0.26
∗In each experiment a group of sixmicewere examined.The values represent
the mean and standard deviation; PC = positive artemether control; NC
= negative 10% Tween 80 control; EtOAc = ethyl acetate extract; MeOH =
methanol extract; isoBuOH = isobutanol extract.
4. Discussion
Despite the overall favorable development in global malaria
incidence and mortality rates, malaria still remains one of the
gravest public health threats to human life in many regions.
Furthermore, the consequences of nonfatal malaria episodes
pose a major economic burden to working age populations
and local communities, especially in many African coun-
tries [5]. The current cost-effective options available in the
prophylaxis and treatment of malaria are, regardless of their
merits, widely considered insufficient to controlmalariamore
efficiently. There is a need for development of new agents
owing to the increasing resistance of the parasite to available
agents [17].
C. macrostachyus leaves [16], crude leaf extract and
chloroform fractions [17], and crude 80% methanol extracts
of the fruit and root [18] have been shown to possess
antimalarial activity against Plasmodium berghei in mice.
We have recently shown antimicrobial activity of Croton
macrostachyusH. (Euphorbiaceae) stem bark extracts against
several human pathogenic bacteria and a fungus [19]. In
the present study different crude stem bark extracts from C.
macrostachyus induced a decrease in parasite density in vivo.
In vivo antiplasmodial activity can be classified as moderate,
good, and very good if an extract displayed percentage
Table 4: Chemoprotective assay. Suppression of parasitemia (%) in
Plasmodium berghei infected BALB/c mice after treatment with C.




Suppression of Parasitemia (%)
Extract
EtOAc MeOH isoBuOH
500 100 83 92
250 93 65 84
100 74 57 86
PC 99 99 99
∗In each experiment a group of six mice were examined; PC = positive
artemether control; EtOAc= ethyl acetate extract;MeOH=methanol extract;
isoBuOH = isobutanol extract.
parasitemia suppression equal to or greater than 50% at a dose
of 500, 250, and 100mg/kg body weight per day, respectively
[22]. In the present study very good impact was achieved
with ethyl acetate (62%) and isobutanol (73%) extracts (over
50% with 100mg/kg) in the Peters’ 4-day suppressive test.
Methanol (68%) and water (72%) extracts had moderate
activity (over 50% with 500mg/kg of the extracts). In the
chemoprotective assay ethyl acetate (74%), methanol (57%),
and isobutanol extracts (86%) had very good impact (over
50% with 100mg/kg of the extract).
The activity of C. macrostachyus stem bark extracts is
comparable to studies where antiplasmodial activity has
been related to a range of several classes of secondary
plant metabolites including alkaloids and sesquiterpenes,
triterpenes, flavonoids, inonoids, and quassinoids [23].These
mostly amphiphile compounds have been described to pro-
tect erythrocytes against hypotonic hemolysis [24]. Here
we found that the highest percent for the suppression of
parasitemia was obtained with the dose of 500mg/kg of
C. macrostachyus stem bark ethyl acetate extract (100% in
chemoprotective and 82% in Peters’ 4-day suppressive test).
Very good impact (100mg/kg) was achieved with ethyl
acetate extract in the Peters’ 4-day suppressive test (62%) and
in the chemoprotective assay (74%). The main components
of C. macrostachyus stem bark are lupeol, betulin, and fatty
acids [13]. Because of their solubility properties one could
conclude that the isobutanol andmethanol extracts contained
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mixtures of these compounds. According to our previous
work lupeol is extracted from C. macrostachyus stem bark
by ethyl acetate [19]. Lupeol is a pharmacologically active
triterpenoid with several potential medicinal properties.
There was a correlation between changes of the erythrocyte
membrane shape to stomatocytic form and the inhibition of
Plasmodium falciparum growth caused by a tropical plant
Rinorea ilicifolia Kuntze lupeol in vitro [25]. In addition to
indirect activity against P. falciparum [25] lupeol isolated
from other plants has been reported to inhibit the growth
of a several types of bacteria, fungi, and viral species [26–
32]. In the present prophylaxis assay the impact of the most
active ethyl acetate extract containing lupeol is linear and thus
may reflect the indirect effect of lupeol on the erythrocyte
membrane. Activity of lupeol from the leaf hexane extract
of Vernonia brasiliana (L.) Druce (Compositae) against P.
falciparum has been shown in vitro [33]. However, lupeol was
found to be inactive in vivowhen 15mg/kg was administered
per os during four consecutive days to mice infected with
P. berghei. In our study, two-, four-, and tenfold higher
doses of lupeol in the ethyl acetate extract (predominant
compound of 27.5%) were administrated per os. The activity
implied chemoprotective, indirect activity on the erythrocyte
membranes and was not found in the Peters’ suppressive test
supporting the results by De Almeida Alves et al., 1997 [33].
However, because of the possible effect of other compounds
or synergistic effect of several compounds present in the
extract the role of lupeol against P. berghei remains here
unsolved and further studies will be needed in future.
In the present study the in vivo assays showed that the
studied extracts ofC. macrostachyuswere able to significantly
suppress the amount of the parasites in infected Balb/c mice.
According to the Tukey’s test the suppression of parasitemia
was even comparable to the control drug artemether as
regards ethyl acetate (500mg/kg) and isobutanol extracts
(down to 100mg/kg) in Peters’ 4-day suppressive test (𝑝 <
0.001) and ethyl acetate (down to 250mg/kg) and isobutanol
(500mg/kg) extracts (𝑝 < 0.001) in the chemoprotective
assay.
The most potential antimalarial chemotherapeutic and
chemoprotective agent of the studied extracts was the ethyl
acetate extract. The isobutanol extract was effective in the
suppression of the parasitemia but the highest dose was
lethal in the acute toxicity test (500mg/kg). Thus it can
be considered as potential antimalarial drug only in low
doses, although all the mice survived in the suppressive and
chemoprotective assays. Although the dose-response curves
were not very steep, the extracts displayed suppression of
parasitemia in a dose-dependent manner. The exceptions
were the isobutanol extract in both antimalarial tests and
the ethyl acetate extract in the Peters’ suppressive test. The
effect of isobutanol extract may thus be due to nonspecific
activity. In the suppressive test the reason for the relatively
high impact of the ethyl acetate extract dose 100mg/kg
compared to the dose of 250mg/kg remains unknown but
may reflect nonspecific activity, which excludes the role of
specific compounds like lupeol as the active agents in the
suppressive test.These results are in parallel with the previous
results by Ziegler et al., 2002 [25], who showed that the effect
of lupeol is indirect and is directed to erythrocyte membrane.
In the chemoprotective assay the impact of the ethyl acetate
extract was linear and may imply the indirect role of lupeol.
5. Conclusions
The results obtained in the present study revealed that C.
macrostachyus stem bark extracts (ethyl acetate, methanol,
and isobutanol) have significant antiplasmodial activity
against Plasmodium berghei both in chemotherapeutic and
in chemoprotective way. This upholds folkloric use of the
plant and the earlier studies carried out with leaves, root,
and fruit. The ethyl acetate extract was the most promising
candidate for further drug development. However, the active
compounds of the extracts have not been identified, and the
antimalarial activity of C. macrostachyus may result from a
combination of its secondary metabolites. Further testing of
the active components of C. macrostachyus extracts will be
needed to forward C. macrostachyus based antimalarial drug
development.
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